The market for malignant melanoma drugs is forecast to expand more than seven-fold over the next decade, growing from $210 million in 2010 to $1.5 billion in 2020 in the USA, France, Germany, Italy, Spain, the UK and Japan, says advisory company Decision Resources.
Although this space had been constrained by a dearth of novel therapies in recent years, robust market growth will be driven by highly anticipated drug approvals - most notably Bristol-Myers Squibb’s Yervoy (ipilimumab), and Roche/Genentech/Chugai/Daiichi Sankyo’s Zelboraf (vemurafenib) - which have created significant changes in the treatment of malignant melanoma.
The Decision Resources predictions are a lot less optimistic than the average estimate of three analysts surveyed by Bloomberg, who predict that sales of Yervoy alone could grow to $1.5 billion in 2015 and those of Zelboraf will reach around $890 by that time (The Pharma Letter August 18).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze